Integra LifeSciences Holdings Corp. (IART) experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.
The company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share (EPS) of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshadowed the earnings beat.
For the first quarter of 2025, Integra LifeSciences expects revenue in the range of $375 million to $385 million, well below analyst estimates of around $411.7 million. The company also guided for adjusted EPS between $0.40 and $0.45 for the quarter.
Furthermore, the company's full-year 2025 revenue guidance of $1.65 billion to $1.71 billion fell slightly short of analyst expectations of around $1.71 billion, adding to investor concerns about the company's growth prospects.
Analysts cited the weaker-than-anticipated revenue guidance as the primary reason for the stock's pre-market decline, as investors reevaluated Integra LifeSciences' near-term growth trajectory and potential headwinds.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。